Unicycive Therapeutics (UNCY) Asset Utilization Ratio (2023)

Name: Unicycive Therapeutics (UNCY) Asset Utilization Ratio (2023) | Business Quant
Creator: Business Quant

Unicycive Therapeutics posted quarterly Asset Utilization Ratio of 0.04 for Q4 2023, up 25.84% on a QoQ basis from 0.03 in Q3 2023.

Unicycive Therapeutics (UNCY) has 1 years of Asset Utilization Ratio data on file, last reported at 0.04 in Q4 2023.

For the quarter ending Q4 2023, Asset Utilization Ratio changed N/A year-over-year to 0.04; the trailing twelve-month figure through Dec 2023 stood at 0.04 (changed N/A YoY), and the FY2023 full-year result was 0.08, down 10.02% from the prior year.
Asset Utilization Ratio for Q4 2023 stood at 0.04, up from 0.03 in the prior quarter.
Across five years, Asset Utilization Ratio topped out at 0.06 in Q2 2023 and bottomed at 0.03 in Q3 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	0.60
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	-
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	0.47
7	Evaxion A	62.56 Bn	62.54 Bn	-	0.29
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	0.37
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	0.85
10	Unicycive Therapeutics	181.94 Mn	127.36 Mn	-	-

Download Data 🔒